xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06036511</url>
    </required_header>
    <id_info>
      <org_study_id>23-116</org_study_id>
      <nct_id>NCT06036511</nct_id>
    </id_info>
    <brief_title>Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD</brief_title>
    <acronym>CONCHKAP</acronym>
    <official_title>Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of New Mexico</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>The Mind Research Network</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>University of New Mexico</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>Yes</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this clinical trial is to learn about the effects of Ketamine Assisted&#xD;
        Psychotherapy [KAP] on individuals with Post Traumatic Stress Disorder [PTSD]. The main&#xD;
        questions it aims to answer are:&#xD;
  &#xD;
          1. Does KAP improve symptoms of PTSD?&#xD;
  &#xD;
          2. What changes in brain network connectivity are seen with KAP?&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and&#xD;
        undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete&#xD;
        baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment,&#xD;
        then within 24 hours, an integration session to take advantage of neuroplasticity for optimal&#xD;
        therapeutic progress. Each participant will have two complete KAP sessions (preparation,&#xD;
        treatment, and integration) followed by rsfMRI within approximately 24 hours, and again&#xD;
        approximately two weeks after the completion of the second KAP session. Patients will also&#xD;
        have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be&#xD;
        correlated with changes in connectivity at each rsfMRI.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 2023</start_date>
    <completion_date type="Anticipated">August 2024</completion_date>
    <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <intervention_model_description>This is a single arm, open-label, prospective cohort clinical trial.&#xD;
  No blinding is required for this trial.&#xD;
  A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Clinical outcome: PTSD severity</measure>
      <time_frame>14-21 days</time_frame>
      <description>as defined by change in score on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) following KAP treatments (Assessment Visit 3) compared to baseline (Assessment Visit 1).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Imaging Outcome: Changes in functional connectivity</measure>
      <time_frame>28-35 days</time_frame>
      <description>change in the functional connectivity between vmPFC and amygdala from Baseline to Assessment Visit 4 as measured by fMRI.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Depression severity</measure>
      <time_frame>14-21 days</time_frame>
      <description>Improvement in depression, as indicated by reduced Montgomery-Asberg Depression Rating Scale (MADRS), following KAP treatments (Assessment Visit 3) compared to baseline (Assessment Visit 1).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Persisting effect</measure>
      <time_frame>28-35 days</time_frame>
      <description>The changes in score on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Correlation of clinical and imaging outcomes</measure>
      <time_frame>28-35 days</time_frame>
      <description>Change in connectivity between the vmPFC and amygdala from Assessment Visit 1 to Assessment Visit 4 with degree of PTSD symptom change.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Persisting effect</measure>
      <time_frame>28-35 days</time_frame>
      <description>Concurrent MDD (MADRS) will persist at last evaluation two weeks after completion of active treatment.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">14</enrollment>
    <condition>PTSD</condition>
    <arm_group>
      <arm_group_label>Ketamine Assisted Psychotherapy [KAP]</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Ketamine Hydrochloride</intervention_name>
      <description>This is a single arm, open-label, prospective cohort clinical trial.&#xD;
  No blinding is required for this trial.&#xD;
  A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.</description>
      <arm_group_label>Ketamine Assisted Psychotherapy [KAP]</arm_group_label>
      <other_name>KAP</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Participants may be eligible for enrollment if all the following inclusion criteria&#xD;
               apply within the thirty days prior to first ketamine administration session:&#xD;
  &#xD;
          Between the ages of 18 to 65 years old.&#xD;
  &#xD;
          Meet DSM-5 criteria for Port-Traumatic Stress Disorder [PTSD] based on clinical interview.&#xD;
  &#xD;
          Able to provide informed consent.&#xD;
  &#xD;
          Are proficient in reading and speaking English.&#xD;
  &#xD;
          Agree to refrain from using stimulants during the day of the medication session.&#xD;
  &#xD;
          Agree to refrain from alcohol and cannabis for 24 hours before and the day of medication&#xD;
          session.&#xD;
  &#xD;
          Subjects taking other psychotropic medications (e.g. anti-depressants, anxiolytics,&#xD;
          methadone, buprenorphine, naltrexone) must be maintained on a stable dose for at least four&#xD;
          weeks before study initiation.&#xD;
  &#xD;
          Agree to not operate a car or any other heavy equipment for the rest of the day after the&#xD;
          ketamine administration.&#xD;
  &#xD;
          If necessary, are willing to be contacted via telephone on a daily basis by the therapist&#xD;
          or team after each experiential session.&#xD;
  &#xD;
          Able to identify one or two caregiver support persons who can drive participant home, stay&#xD;
          with them overnight, be reached by the team, and provide collateral information as needed.&#xD;
  &#xD;
          Willing to inform the investigator within 48 hours if any medical conditions occur or&#xD;
          procedures are planned.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Participants will be excluded from the study if any of the following criteria apply:&#xD;
  &#xD;
          They are considered an immediate suicide risk by clinician assessment or felt to be likely&#xD;
          to require hospitalization during the study.&#xD;
  &#xD;
          Have had a psychiatric or medical hospitalization, or an Emergency Department visit, within&#xD;
          four weeks of the study entry.&#xD;
  &#xD;
          Subjects who meet DSM-5 criteria for current bipolar disorder based on clinical interview.&#xD;
  &#xD;
          Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders&#xD;
          based on clinical interview.&#xD;
  &#xD;
          Subjects meeting DSM-5 criteria for current substance use disorder (i.e., not in early or&#xD;
          sustained remission) other than tobacco use disorder.&#xD;
  &#xD;
          Subjects who report use of ketamine &gt;20 times in the past or who meet DSM-5 criteria for&#xD;
          Other Hallucinogen Use Disorder due to ketamine use including subjects who are currently in&#xD;
          early or sustained remission.&#xD;
  &#xD;
          Women who are pregnant or nursing, and women who do not consent to use methods of highly&#xD;
          effective birth control during the study.&#xD;
  &#xD;
          Subjects with hypertension as defined by a baseline visit systolic blood pressure (SBP)&#xD;
          &gt;140 mmHg or a diastolic blood pressure (DBP) &gt;90 mmHg.&#xD;
  &#xD;
          A history of allergic or other adverse reaction to ketamine (or its excipients).&#xD;
  &#xD;
          Clinically significant physical exam findings or self-reported medical conditions for which&#xD;
          a transient increase in blood pressure could be significantly detrimental (e.g. glaucoma,&#xD;
          aneurysmal disease, cardiovascular disease, or end-stage renal disease).&#xD;
  &#xD;
          QTc will be measured in all subjects and those with QTc 450ms or longer will be excluded.&#xD;
  &#xD;
          High risk of adverse emotional or behavioral reaction based on investigator's clinical&#xD;
          evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious&#xD;
          current stressors, lack of meaningful social support).&#xD;
  &#xD;
          Documented evidence of significant renal or hepatic dysfunction at screening. Significantly&#xD;
          impaired liver function is defined as 1) Alanine aminotransferase (ALT) and/or aspartate&#xD;
          aminotransferase (AST) &gt; 5 × upper limit of normal (ULN); 2) ALT or AST &gt; 3 × ULN with&#xD;
          concomitant total bilirubin &gt; 2.0 × ULN; or 3) ALT or AST ≥ 3 × ULN with the appearance of&#xD;
          fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or&#xD;
          eosinophilia.&#xD;
  &#xD;
          Blood pressure will be monitored at all subsequent visits, and participants will receive&#xD;
          study medication only if blood pressure is less than or equal to 140 systolic, 90 diastolic&#xD;
          at safety screening on the day of the drug administration sessions.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>65 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Snehal Bhatt, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>UNM</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Lindsay Worth, MS</last_name>
      <phone>505-994-7999</phone>
      <email>lindsayw@salud.unm.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>University of New Mexico</name>
        <address>
          <city>Albuquerque</city>
          <state>New Mexico</state>
          <zip>87106</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Snehal Bhatt</last_name>
        <phone>505-994-7999</phone>
        <email>sbhatt@salud.unm.edu</email>
      </contact>
      <investigator>
        <last_name>Jon Houck, PhD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
      <investigator>
        <last_name>Snehal Bhatt, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
      <investigator>
        <last_name>Davin Quinn, MD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
      <investigator>
        <last_name>Lucas Dunklee, MD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Drozdz SJ, Goel A, McGarr MW, Katz J, Ritvo P, Mattina GF, Bhat V, Diep C, Ladha KS. Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. J Pain Res. 2022 Jun 15;15:1691-1706. doi: 10.2147/JPR.S360733. eCollection 2022.</citation>
      <PMID>35734507</PMID>
    </reference>
    <reference>
      <citation>Joneborg I, Lee Y, Di Vincenzo JD, Ceban F, Meshkat S, Lui LMW, Fancy F, Rosenblat JD, McIntyre RS. Active mechanisms of ketamine-assisted psychotherapy: A systematic review. J Affect Disord. 2022 Oct 15;315:105-112. doi: 10.1016/j.jad.2022.07.030. Epub 2022 Jul 26.</citation>
      <PMID>35905796</PMID>
    </reference>
    <reference>
      <citation>Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019 Apr-Jun;51(2):189-198. doi: 10.1080/02791072.2019.1587556. Epub 2019 Mar 27.</citation>
      <PMID>30917760</PMID>
    </reference>
    <reference>
      <citation>Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021 Feb 1;178(2):193-202. doi: 10.1176/appi.ajp.2020.20050596. Epub 2021 Jan 5.</citation>
      <PMID>33397139</PMID>
    </reference>
    <reference>
      <citation>Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin P, Shapero BG, Deckersbach T. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature. Harv Rev Psychiatry. 2018 Nov/Dec;26(6):320-339. doi: 10.1097/HRP.0000000000000179.</citation>
      <PMID>29465479</PMID>
    </reference>
    <reference>
      <citation>Norbury A, Rutter SB, Collins AB, Costi S, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Glasgow AM, Brallier J, Shin LM, Charney DS, Murrough JW, Feder A. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology. 2021 Dec;46(13):2266-2277. doi: 10.1038/s41386-021-01104-4. Epub 2021 Jul 31.</citation>
      <PMID>34333555</PMID>
    </reference>
    <reference>
      <citation>Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Curr Psychiatry Rep. 2017 Aug 26;19(10):74. doi: 10.1007/s11920-017-0829-z.</citation>
      <PMID>28844076</PMID>
    </reference>
    <reference>
      <citation>Patel R, Spreng RN, Shin LM, Girard TA. Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev. 2012 Oct;36(9):2130-42. doi: 10.1016/j.neubiorev.2012.06.003. Epub 2012 Jul 2.</citation>
      <PMID>22766141</PMID>
    </reference>
    <reference>
      <citation>Sheynin J, Liberzon I. Circuit dysregulation and circuit-based treatments in posttraumatic stress disorder. Neurosci Lett. 2017 May 10;649:133-138. doi: 10.1016/j.neulet.2016.11.014. Epub 2016 Nov 12.</citation>
      <PMID>27845239</PMID>
    </reference>
    <reference>
      <citation>Stopyra MA, Simon JJ, Rheude C, Nikendei C. Pathophysiological aspects of complex PTSD - a neurobiological account in comparison to classic posttraumatic stress disorder and borderline personality disorder. Rev Neurosci. 2022 Aug 8;34(1):103-128. doi: 10.1515/revneuro-2022-0014. Print 2023 Jan 27.</citation>
      <PMID>35938987</PMID>
    </reference>
    <reference>
      <citation>Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, Weiss ME, Thompson AL, Zack SE, Lindley SE, Arnow BA, Jo B, Rothbaum BO, Etkin A. Amygdala and Insula Connectivity Changes Following Psychotherapy for Posttraumatic Stress Disorder: A Randomized Clinical Trial. Biol Psychiatry. 2021 May 1;89(9):857-867. doi: 10.1016/j.biopsych.2020.11.021. Epub 2020 Dec 8.</citation>
      <PMID>33516458</PMID>
    </reference>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 3, 2023</study_first_submitted>
    <study_first_submitted_qc>September 6, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 14, 2023</study_first_posted>
    <last_update_submitted>September 6, 2023</last_update_submitted>
    <last_update_submitted_qc>September 6, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>University of New Mexico</investigator_affiliation>
      <investigator_full_name>Snehal Bhatt, MD</investigator_full_name>
      <investigator_title>Chief, Addiction Psychiatry</investigator_title>
    </responsible_party>
    <keyword>PTSD</keyword>
    <keyword>Ketamine Assisted Psychotherapy</keyword>
    <keyword>Brain network connectivity</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Ketamine</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06036511
  org study id: 23-116
  nct id: NCT06036511
  lead sponsor: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  is us export: Yes
  The goal of this clinical trial is to learn about the effects of Ketamine Assisted
        Psychotherapy [KAP] on individuals with Post Traumatic Stress Disorder [PTSD]. The main
        questions it aims to answer are:
  
          1. Does KAP improve symptoms of PTSD?
  
          2. What changes in brain network connectivity are seen with KAP?
  A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and
        undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete
        baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment,
        then within 24 hours, an integration session to take advantage of neuroplasticity for optimal
        therapeutic progress. Each participant will have two complete KAP sessions (preparation,
        treatment, and integration) followed by rsfMRI within approximately 24 hours, and again
        approximately two weeks after the completion of the second KAP session. Patients will also
        have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be
        correlated with changes in connectivity at each rsfMRI.
  allocation: N/A
  intervention model: Single Group Assignment
  intervention model description: This is a single arm, open-label, prospective cohort clinical trial.
  No blinding is required for this trial.
  A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Clinical outcome: PTSD severity
  time frame: 14-21 days
  description: as defined by change in score on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) following KAP treatments (Assessment Visit 3) compared to baseline (Assessment Visit 1).
  measure: Imaging Outcome: Changes in functional connectivity
  time frame: 28-35 days
  description: change in the functional connectivity between vmPFC and amygdala from Baseline to Assessment Visit 4 as measured by fMRI.
  measure: Depression severity
  time frame: 14-21 days
  description: Improvement in depression, as indicated by reduced Montgomery-Asberg Depression Rating Scale (MADRS), following KAP treatments (Assessment Visit 3) compared to baseline (Assessment Visit 1).
  measure: Persisting effect
  time frame: 28-35 days
  description: The changes in score on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
  measure: Correlation of clinical and imaging outcomes
  time frame: 28-35 days
  description: Change in connectivity between the vmPFC and amygdala from Assessment Visit 1 to Assessment Visit 4 with degree of PTSD symptom change.
  measure: Persisting effect
  time frame: 28-35 days
  description: Concurrent MDD (MADRS) will persist at last evaluation two weeks after completion of active treatment.
  arm group label: Ketamine Assisted Psychotherapy [KAP]
  arm group type: Experimental
  description: A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
  intervention type: Drug
  intervention name: Ketamine Hydrochloride
  description: This is a single arm, open-label, prospective cohort clinical trial.
  No blinding is required for this trial.
  A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
  arm group label: Ketamine Assisted Psychotherapy [KAP]
  other name: KAP
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 65 Years
  healthy volunteers: No
  last name: Snehal Bhatt, MD
  role: Principal Investigator
  affiliation: UNM
  last name: Lindsay Worth, MS
  phone: 505-994-7999
  email: lindsayw@salud.unm.edu
  facility: 
  contact: 
  investigator: 
  investigator: 
  investigator: 
  investigator: 
  country: United States
  citation: Drozdz SJ, Goel A, McGarr MW, Katz J, Ritvo P, Mattina GF, Bhat V, Diep C, Ladha KS. Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. J Pain Res. 2022 Jun 15;15:1691-1706. doi: 10.2147/JPR.S360733. eCollection 2022.
  PMID: 35734507
  citation: Joneborg I, Lee Y, Di Vincenzo JD, Ceban F, Meshkat S, Lui LMW, Fancy F, Rosenblat JD, McIntyre RS. Active mechanisms of ketamine-assisted psychotherapy: A systematic review. J Affect Disord. 2022 Oct 15;315:105-112. doi: 10.1016/j.jad.2022.07.030. Epub 2022 Jul 26.
  PMID: 35905796
  citation: Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019 Apr-Jun;51(2):189-198. doi: 10.1080/02791072.2019.1587556. Epub 2019 Mar 27.
  PMID: 30917760
  citation: Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021 Feb 1;178(2):193-202. doi: 10.1176/appi.ajp.2020.20050596. Epub 2021 Jan 5.
  PMID: 33397139
  citation: Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin P, Shapero BG, Deckersbach T. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature. Harv Rev Psychiatry. 2018 Nov/Dec;26(6):320-339. doi: 10.1097/HRP.0000000000000179.
  PMID: 29465479
  citation: Norbury A, Rutter SB, Collins AB, Costi S, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Glasgow AM, Brallier J, Shin LM, Charney DS, Murrough JW, Feder A. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology. 2021 Dec;46(13):2266-2277. doi: 10.1038/s41386-021-01104-4. Epub 2021 Jul 31.
  PMID: 34333555
  citation: Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Curr Psychiatry Rep. 2017 Aug 26;19(10):74. doi: 10.1007/s11920-017-0829-z.
  PMID: 28844076
  citation: Patel R, Spreng RN, Shin LM, Girard TA. Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev. 2012 Oct;36(9):2130-42. doi: 10.1016/j.neubiorev.2012.06.003. Epub 2012 Jul 2.
  PMID: 22766141
  citation: Sheynin J, Liberzon I. Circuit dysregulation and circuit-based treatments in posttraumatic stress disorder. Neurosci Lett. 2017 May 10;649:133-138. doi: 10.1016/j.neulet.2016.11.014. Epub 2016 Nov 12.
  PMID: 27845239
  citation: Stopyra MA, Simon JJ, Rheude C, Nikendei C. Pathophysiological aspects of complex PTSD - a neurobiological account in comparison to classic posttraumatic stress disorder and borderline personality disorder. Rev Neurosci. 2022 Aug 8;34(1):103-128. doi: 10.1515/revneuro-2022-0014. Print 2023 Jan 27.
  PMID: 35938987
  citation: Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, Weiss ME, Thompson AL, Zack SE, Lindley SE, Arnow BA, Jo B, Rothbaum BO, Etkin A. Amygdala and Insula Connectivity Changes Following Psychotherapy for Posttraumatic Stress Disorder: A Randomized Clinical Trial. Biol Psychiatry. 2021 May 1;89(9):857-867. doi: 10.1016/j.biopsych.2020.11.021. Epub 2020 Dec 8.
  PMID: 33516458
  responsible party type: Principal Investigator
  investigator affiliation: University of New Mexico
  investigator full name: Snehal Bhatt, MD
  investigator title: Chief, Addiction Psychiatry
  mesh term: Stress Disorders, Post-Traumatic
  mesh term: Ketamine
  sharing ipd: No